AZD4144 not checked

AstraZeneca

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
11 in total · 4 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Intravenous solution of AZD4144 will be administered to randomised participants according to the treatment arm to which they have been assigned.”In the company’s words, NCT07215702 on ClinicalTrials.gov
Tested for
Sepsis, Acute Kidney Injury, Hepatic Impairment
Main trialPhase 2
“This study will enroll adults aged 18 to 80 years diagnosed with sepsis due to a suspected or confirmed bacterial infection, within 7 days of being admitted to the hospital, and who have also developed acute kidney injury within 72 hours of the onset of sepsis. Eligible participants will be randomly assigned to receive either AZD4144 or a placebo intravenously once daily for the number of days specified in the CSP. During this Treatment Period, participants will undergo daily safety monitoring, as well as blood and urine sample collection and other assessments. After the Treatment Period,…”In the company’s words, NCT07215702 on ClinicalTrials.gov

Other drugs for Sepsis

All 10 drugs for Sepsis

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials11

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 11 Feb 2027 A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
Phase 1Not yet recruiting 28 May 2027 A Phase I Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD4144
Phase 1Completed 4 Dec 2024 A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants
Phase 1Completed 23 Apr 2025 A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of AZD4144 in Participants With Severe Renal Impairment, End-stage Kidney Disease, and in Healthy Participants
Phase 1Completed 11 Jun 2025 A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants
Phase 1Completed 12 Jun 2025 A Study to Investigate How AZD4144 Affects the Pharmacokinetics of Rosuvastatin in Healthy Participants
Phase 1Completed 27 Jun 2025 A Study to Investigate the Relative Bioavailability of 2 Different Formulations of AZD4144, the Effect of Food and Omeprazole on the Pharmacokinetics of AZD4144 in Healthy Participants
Phase 1Completed 29 Sep 2025 A Study to Investigate the Safety, Tolerability and Pharmacodynamics of AZD4144 in Participants With Obesity
Phase 1Completed 27 Oct 2025 A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease.
Phase 1Completed 26 May 2026 A Study of Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]AZD4144
Phase 1Completed 22 Oct 2026 Investigating the Effect of Itraconazole on the Pharmacokinetics of AZD4144 in Healthy Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow AZD4144

Following is part of Solo: you see every change to AZD4144 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in